All posts by: Michael Zand

About Michael Zand

Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR – GlobeNewswire (press release)

Continue reading

2017-04-04 NEWS

Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR–T / TCR Technology at AACR
GlobeNewswire (press release)
In a late-breaking poster presentation titled “Dual-switch HER2 CAR–T cells: Small molecule-regulated GO and STOP switches to target solid cancer in vivo,” Bellicum scientists tested the novel dual-switch platform in solid tumors by combining both the …

and more »

Continue reading

2017-04-04 NEWS

Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR–T / TCR Technology at AACR
GlobeNewswire (press release)
In a late-breaking poster presentation titled “Dual-switch HER2 CAR–T cells: Small molecule-regulated GO and STOP switches to target solid cancer in vivo,” Bellicum scientists tested the novel dual-switch platform in solid tumors by combining both the …

Continue reading

2017-04-04 NEWS

Bellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR–T / TCR Technology at AACR
Nasdaq
In a late-breaking poster presentation titled “Dual-switch HER2 CAR–T cells: Small molecule-regulated GO and STOP switches to target solid cancer in vivo,” Bellicum scientists tested the novel dual-switch platform in solid tumors by combining both the …

and more »

Continue reading

2017-04-04 NEWS

Bellicum Pharma (BLCM) to Present Preclinical Data on CAR–T and TCR Product Candidates at AACR
StreetInsider.com
In a late-breaking poster presentation titled “Dual-switch HER2 CAR–T cells: Small molecule-regulated GO and STOP switches to target solid cancer in vivo,” Bellicum scientists tested the novel dual-switch platform in solid tumors by combining both the …

and more »